Celldex Therapeutics, Inc. (CLDX): Shareholders' Equity
$527.16M
As of 2025-12-31
$714.56M
As of 2026-06-30
+17.4%
3-year compound annual growth
+20.3%
5-year compound annual growth
+6.2%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $527.16M | -29.4% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $747.00M | +74.1% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $429.17M | +31.6% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $326.20M | -22.2% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $419.48M | +100.4% | 2024-02-26, Balance as of period end |
| 2020-12-31 | $209.36M | +122.7% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $94.03M | -24.2% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $124.06M | -47.5% | 2021-03-29, Balance as of period end |
| 2017-12-31 | $236.37M | -10.9% | 2020-03-26, Balance as of period end |
| 2016-12-31 | $265.43M | -8.5% | 2019-03-07, Balance as of period end |
| 2015-12-31 | $290.11M | +37.1% | 2018-03-07, Balance as of period end |
| 2014-12-31 | $211.66M | -33.8% | 2017-03-14, Balance as of period end |
| 2013-12-31 | $319.80M | +233.9% | 2016-02-25, Balance as of period end |
| 2012-12-31 | $95.77M | +39.4% | 2015-02-24, Balance as of period end |
| 2011-12-31 | $68.72M | -8.7% | 2014-03-03, Balance as of period end |
| 2010-12-31 | $75.25M | +2.0% | 2013-03-08, Balance as of period end |
| 2009-12-31 | $73.77M | n/a | 2012-03-08, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $527.16M | -29.4% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | -$34.25M | n/m |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | -$31.46M | n/m |
| Biomerica Inc (BMRA) | 2026-05-31 | $2.63M | -35.9% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $30.16M | +75.4% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$6.93M | n/m |
| Immucell Corp (ICCC) | 2025-12-31 | $27.06M | -1.7% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $68.78M | -16.5% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $671.39M | -23.0% |
Compare CLDX, VNRX, IMDX, BMRA side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗